Martin Ehrenschwender

12PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 26, 2020
Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer.

Sina Heimer, Gertrud Knoll, Patrick Neubert

|Jul 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 Treatment.

Valentina Volpin, Tillmann Michels, Antonio Sorrentino

|Apr 22, 2020
NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and "osmotic reprogramming" in colorectal cancer.

Gertrud Knoll, Petra Riffelsberger, Danielle Raats

|Jul 21, 2019
Raptinal bypasses BAX, BAK, and BOK for mitochondrial outer membrane permeabilization and intrinsic apoptosis.

Sina Heimer, Gertrud Knoll, Klaus Schulze-Osthoff

Pageof 2